GSK to rein in DTC TV

Share this article:

GlaxoSmithKline will ratchet down its DTC TV advertising in light of ongoing controversy around the medium, according to statements made by CEO Andrew Witty in The Wall Street Journal.

Without getting into specifics, Witty told the paper that the company would do less TV advertising in 2009 than it has in the past. He also noted that consumer advertising does help educate viewers on diseases and treatment options. 

Witty's decision to cut back on DTC TV spots comes as drug companies anticipate an increasingly stringent atmosphere for consumer advertising in Washington, as well as a dearth of new blockbuster drugs and a plague of patent expirations on old ones. GSK spent 23% less on consumer advertising during the first half of 2008, The Wall Street Journal reported -- due in large measure to a freeze on advertising of diabetes drug Avandia. 

Manufacturers spent 4% less ($3.69 billion) on consumer advertising during the first three quarters of 2008, down from $3.86 billion over the same period in 2007, according to Nielsen. In December, PhRMA tweaked its consumer advertising guidelines in an effort to blunt congressional momentum for new regulations on drug ads.

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...